A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

372

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: disitamab vedotin
DRUG: pembrolizumab

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Collaborators

[object Object]